PDCD1 and precursor B-cell acute lymphoblastic leukemia: To determine whether the therapeutic effect of PD-1 targeting in B-ALL mice is dependent on T or NK cells, we repeated the checkpoint targeting strategy (Figure 4) in NOD/SCID mice, which lack B and T cells and have defective natural killer (NK) cell function.